Fri, March 18, 2022
Thu, March 17, 2022
Wed, March 16, 2022
Tue, March 15, 2022
Mon, March 14, 2022
Fri, March 11, 2022
Thu, March 10, 2022
Wed, March 9, 2022

Raghuram Selvaraju Maintained (BTAI) at Strong Buy with Decreased Target to $130 on, Mar 14th, 2022


  Copy link into your clipboard //stocks-investing.news-articles.net/content/202 .. th-decreased-target-to-130-on-mar-14th-2022.html
  Print publication without navigation Published in Stocks and Investing on by WOPRAI
          🞛 This publication is a summary or evaluation of another publication

Raghuram Selvaraju of HC Wainwright & Co., Maintained "BioXcel Therapeutics, Inc." (BTAI) at Strong Buy with Decreased Target from $140 to $130 on, Mar 14th, 2022.

Raghuram has made no other calls on BTAI in the last 4 months.



There are 2 other peers that have a rating on BTAI. Out of the 2 peers that are also analyzing BTAI, 0 agree with Raghuram's Rating of Hold.



These are the ratings of the 2 analyists that currently disagree with Raghuram


  • Colin Bristow of "UBS" Maintained at Strong Buy with Decreased Target to $25 on, Wednesday, February 16th, 2022
  • Corinne Jenkins of "Goldman Sachs" Downgraded from Strong Buy to Strong Sell and Decreased Target to $24 on, Monday, November 15th, 2021

Publication Contributing Sources